Etavopivat tablets · Hematology/Rare Blood Disorders Etavopivat activates the protein kinase PKC (protein kinase C) to increase fetal hemoglobin (HbF) production, thereby reducing sickling and hemolysis in red blood cells.
Etavopivat Tablets High dose · Hematology/Rare Blood Disorders Etavopivat activates the Nrf2 (nuclear factor erythroid 2-related factor 2) pathway to increase antioxidant defenses and reduce hemolysis in red blood cells.
Etavopivat Tablets Low dose · Hematology/Oncology Etavopivat activates the KCNQ1 potassium channel to increase fetal hemoglobin (HbF) production in red blood cells.